Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
10,000+ US Securities
Unlisted Companies not available on US Stock Exchanges
Professionally managed portfolios, designed by Vested’s research team
Get exposure to 50+ countries via global funds managed by the world’s top fund managers
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together.
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning.
Read about our journey and get to know the leadership team at Vested
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The Company is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. It is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP. Its subsidiary, Grid AI Corp., is an artificial intelligence (AI)-driven, grid-edge software and device orchestration platform. more
| Time Frame | GRDX | S&P500 | |
|---|---|---|---|
| 1-Week Return | -18.64%% | % | 0.95%% |
| 1-Month Return | -43.81%% | % | -0.27%% |
| 3-Month Return | -17.15%% | % | 6.43%% |
| 6-Month Return | 71.97%% | % | 14.99%% |
| 1-Year Return | 64.49%% | % | 12.9%% |
| 3-Year Return | -99.36%% | % | 67.53%% |
| 5-Year Return | -100%% | % | 85.92%% |
| 10-Year Return | -100%% | % | 227.74%% |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| GRDX | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| GRDX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
GridAI Technologies Corp (GRDX) share price today is $2.31
Yes, Indians can buy shares of GridAI Technologies Corp (GRDX) on Vested. To buy GridAI Technologies Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GRDX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of GridAI Technologies Corp (GRDX) via the Vested app. You can start investing in GridAI Technologies Corp (GRDX) with a minimum investment of $1.
You can invest in shares of GridAI Technologies Corp (GRDX) via Vested in three simple steps:
The 52-week high price of GridAI Technologies Corp (GRDX) is $5.84. The 52-week low price of GridAI Technologies Corp (GRDX) is $0.97.
The price-to-book (P/B) ratio of GridAI Technologies Corp (GRDX) is 0.00
The market capitalization of GridAI Technologies Corp (GRDX) is $7.63M
The stock symbol (or ticker) of GridAI Technologies Corp is GRDX
Link copied